Changes in penile length after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy. (2nd July 2018)

• Record Type: Journal Article
• Authors: Kadono, Y.; Nohara, T.; Kawaguchi, S.; Sakamoto, J.; Makino, T.; Nakashima, K.; Iijima, M.; Shigehara, K.; Izumi, K.; Mizokami, A.
• Is Part Of: Andrology. Volume 6:Number 6(2018)
• Page Start: 903
• Page End: 908
• Publication Date: 2018-07-02
• Subjects: androgen deprivation therapy -- neoadjuvant -- penile length -- radical prostatectomy; Andrology -- Periodicals; 616.65
• DOI: 10.1111/andr.12517
• Languages: English
• ISSNs: 2047-2919

Abstract

Summary: Although reports have shown evidence for penile length (PL) shortening after radical prostatectomy (RP), the association between neoadjuvant androgen deprivation therapy (NADT) and PL after RP has yet to be determined. This study evaluates chronological changes in PL after NADT and RP. Stretched PLs (SPLs) of 143 patients, 41 of whom had undergone NADT, were measured before, 10 days after, and 1, 3, 6, 9, 12, 18, and 24 months after RP. Chronological erectile function and testosterone levels were then evaluated. SPL was shortest 10 days after RP in both the NADT (−) and NADT (+) groups and gradually recovered in length thereafter. SPL in the NADT (−) group was significantly longer than that in the NADT (+) group before RP. However, no significant differences in SPLs were found between both groups 6 months after RP. Although all subjects in the NADT (+) group had testosterone levels of <50 ng/dL before RP, such levels increased after RP. Before RP, the NADT (−) group was found to have significantly better erectile function than the NADT (+) group. However, differences in erectile function between the NADT (−) and NADT (+) groups after RP were not significant. This report is the first to show that among patients with prostate cancer, those who underwent NADT had greater PL recovery after RP than those who did not. Data regarding PL recovery after NADT and RP obtained in this study could be useful for patients with prostate cancer who plan to undergo such procedures.